Microbot Medical Cash And Equivalents vs. EBITDA
| CY9D Stock | EUR 0.97 0.04 4.30% |
For Microbot Medical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Microbot Medical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Microbot Medical utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Microbot Medical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Microbot Medical over time as well as its relative position and ranking within its peers.
Microbot |
Microbot Medical EBITDA vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Microbot Medical's current stock value. Our valuation model uses many indicators to compare Microbot Medical value to that of its competitors to determine the firm's financial worth. Microbot Medical is number one stock in cash and equivalents category among its peers. It also is number one stock in ebitda category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Microbot Medical's earnings, one of the primary drivers of an investment's value.Microbot EBITDA vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Microbot Medical |
| = | 20.62 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Microbot Medical |
| = | (11.28 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Microbot EBITDA Comparison
Microbot Medical is currently under evaluation in ebitda category among its peers.
Microbot Medical Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Microbot Medical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Microbot Medical will eventually generate negative long term returns. The profitability progress is the general direction of Microbot Medical's change in net profit over the period of time. It can combine multiple indicators of Microbot Medical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts. MICROBOT MEDICAL operates under Medical Instruments Supplies classification in Germany and is traded on Frankfurt Stock Exchange. It employs 14 people.
Microbot Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Microbot Medical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Microbot Medical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Microbot Medical's important profitability drivers and their relationship over time.
Use Microbot Medical in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Microbot Medical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Microbot Medical will appreciate offsetting losses from the drop in the long position's value.Microbot Medical Pair Trading
Microbot Medical Pair Trading Analysis
The ability to find closely correlated positions to Microbot Medical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microbot Medical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microbot Medical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microbot Medical to buy it.
The correlation of Microbot Medical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microbot Medical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microbot Medical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microbot Medical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Microbot Medical position
In addition to having Microbot Medical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Growth Funds Thematic Idea Now
Small Growth Funds
Funds or Etfs that invest in stocks of small to mid-sized companies with above-average risk and growth rate that usually reinvest their earnings back into business. The Small Growth Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Growth Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Microbot Stock
When determining whether Microbot Medical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Microbot Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Microbot Medical Stock. Highlighted below are key reports to facilitate an investment decision about Microbot Medical Stock:Check out Trending Equities. For more detail on how to invest in Microbot Stock please use our How to Invest in Microbot Medical guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
To fully project Microbot Medical's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Microbot Medical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Microbot Medical's income statement, its balance sheet, and the statement of cash flows.